Bracco molecular imaging subsidiary Blue Earth Diagnostics has acquired exclusive, worldwide rights to therapeutic applications of radiohybrid prostate-specific membrane antigen (rhPSMA) technology developed by German radiopharmaceutical firm Scintomics and the Technical University of Munich (TUM).
The deal follows on Blue Earth's 2018 purchase of exclusive rights to imaging applications of the rhPSMA technology for prostate cancer. The rhPSMA technology is a theranostic radiohybrid platform that is capable of labeling prostate cancer cells in conjunction with either PET imaging radiopharmaceuticals such as fluorine-18 (F-18) or therapeutic radioisotopes such as lutetium-177 (Lu-177) and actinium-225 (Ac-225), according to the company.
Blue Earth said it would drive development of a lead radiolabeled rhPSMA therapeutic compound and continue to collaborate with the TUM to identify additional therapeutic candidates for future development. The vendor also noted that two phase III clinical trials are currently investigating the use of the rhPSMA-7.3 lead candidate in PET imaging of prostate cancer, according to Blue Earth.
